The GLP-1 Demand Spillover
2 filers across 2 sectors are noting demand. First observed in 2026Q1; no trajectory yet. Primarily a demand story (67%), with a risk overlay (33%). Forward-leaning — companies are guiding to this, not just explaining the past. Recent filings describe "Changes to dietary guidelines or use of weight-loss medications drive popular opinion and alter consumer behavior in ways that affect the IEO segment." Too early to confirm a trajectory.
Pharmaceutical expansion of obesity-medicine access via Medicaid is creating downstream consumer behavior shifts that affect food and beverage demand, particularly in indulgence-oriented segments.
DISTINCT NEW FILERS PER QUARTER
✦ WHAT THE DIFF CAUGHT
Language shifts from LLY's supply-side uncertainty about uptake to MCD's demand-side recognition that widespread medication adoption will disrupt eating patterns and category preference.
REPRESENTATIVE SIGNAL FROM FILINGS
“Changes to dietary guidelines or use of weight-loss medications drive popular opinion and alter consumer behavior in ways that affect the IEO segment.”
Evolving dietary guidelines and weight-loss medication adoption may alter consumer behavior and affect demand for the IEO segment.
“The uptake from this expanded access is unknown”
The uptake from expanded access to obesity medicines is unknown.
DRIVERS